Alfred J. Ford Jr - Jan 13, 2023 Form 4 Insider Report for Axonics, Inc. (AXNX)

Role
Chief Commercial Officer
Signature
/s/ Dan Dearen, as Attorney-in-Fact for Alfred J. Ford, Jr.
Stock symbol
AXNX
Transactions as of
Jan 13, 2023
Transactions value $
-$1,904,598
Form type
4
Date filed
1/18/2023, 07:03 PM
Previous filing
Feb 3, 2022
Next filing
Feb 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXNX Common Stock Options Exercise $12.1K +8.51K +23.14% $1.42* 45.3K Jan 13, 2023 Direct
transaction AXNX Common Stock Options Exercise $3.1K +1.9K +4.19% $1.63* 47.2K Jan 13, 2023 Direct
transaction AXNX Common Stock Options Exercise $240K +9.31K +19.73% $25.82 56.5K Jan 13, 2023 Direct
transaction AXNX Common Stock Options Exercise $231K +16.3K +28.85% $14.19 72.8K Jan 13, 2023 Direct
transaction AXNX Common Stock Sale -$1.01M -15.3K -21.01% $65.90 57.5K Jan 13, 2023 Direct F1
transaction AXNX Common Stock Sale -$1.14M -17.1K -29.76% $66.69 40.4K Jan 13, 2023 Direct F2
transaction AXNX Common Stock Sale -$243K -3.62K -8.95% $67.18 36.8K Jan 13, 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AXNX Stock Option (Right to Buy) Options Exercise $0 -9.31K -66.67% $0.00 4.66K Jan 13, 2023 Common Stock 9.31K $25.82 Direct F4
transaction AXNX Stock Option (Right to Buy) Options Exercise $0 -16.3K -100% $0.00* 0 Jan 13, 2023 Common Stock 16.3K $14.19 Direct F5
transaction AXNX Stock Option (Right to Buy) Options Exercise $0 -1.9K -100% $0.00* 0 Jan 13, 2023 Common Stock 1.9K $1.63 Direct F6
transaction AXNX Stock Option (Right to Buy) Options Exercise $0 -8.51K -100% $0.00* 0 Jan 13, 2023 Common Stock 8.51K $1.42 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $65.05 USD to $66.04 USD; the price reported above reflects the weighted average sale price.
F2 This transaction was executed in multiple trades at prices ranging from $66.085 USD to $67.08 USD; the price reported above reflects the weighted average sale price.
F3 This transaction was executed in multiple trades at prices ranging from $67.13 USD to $67.215 USD; the price reported above reflects the weighted average sale price.
F4 The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on December 12, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on December 12, 2023, provided the reporting person remains in continuous service on each vesting date.
F5 The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on January 30, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on January 30, 2023, provided the reporting person remains in continuous service on each vesting date.
F6 The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on March 30, 2018 and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of March 30, 2018, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.
F7 The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on November 15, 2017 and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of November 15, 2017, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.